An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient
Immunotherapy with immune checkpoint inhibitors (ICI) is a new option of treatment in a growing range of neoplasms. In addition to an antitumor effect, ICI are associated with autoimmune reactions resulting in a wide spectrum of toxicities that have not been seen in patients receiving chemotherapy....
Saved in:
Main Authors: | Kinga Krukowska, Robert Kieszko, Katarzyna Kurek, Izabela Chmielewska, Paweł Krawczyk, Janusz Milanowski |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | Case Reports in Oncological Medicine |
Online Access: | http://dx.doi.org/10.1155/2020/4196178 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC: Real-world evidence
by: Irina Surovtsova, et al.
Published: (2025-12-01) -
A Curious Case of Pseudothrombocytopenia due to In Vitro Agglutination
by: Le Zhong, et al.
Published: (2020-01-01) -
Ethylenediaminetetraacetic acid-dependent pseudothrombocytopenia, presenting as spurious pancytopenia, associated with risperidone
by: Harkishan Mamtani, et al.
Published: (2023-03-01) -
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis
by: Jeff Clarke, et al.
Published: (2025-02-01) -
Pseudothrombocytopenia due to Platelet Clumping: A Case Report and Brief Review of the Literature
by: Geok Chin Tan, et al.
Published: (2016-01-01)